Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| CMSC | 0.09% | 22.03 | $ | |
| RBGPF | 100% | 67.21 | $ | |
| RYCEF | -0.99% | 10.12 | $ | |
| RIO | -1.45% | 58.55 | $ | |
| BTI | -0.58% | 43.3 | $ | |
| AZN | -1.82% | 70.51 | $ | |
| RELX | -1.02% | 54.08 | $ | |
| NGG | -1.88% | 71.65 | $ | |
| VOD | -0.31% | 9.73 | $ | |
| GSK | -2.84% | 38.75 | $ | |
| CMSD | -0.18% | 22.26 | $ | |
| JRI | 0.77% | 13.01 | $ | |
| SCS | -0.51% | 9.87 | $ | |
| BP | 1.51% | 27.88 | $ | |
| BCC | -0.61% | 92.71 | $ | |
| BCE | -3.78% | 21.44 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
O.Leclercq--JdB
